Teva Pharmaceutical Industries (TEVA)
(Real Time Quote from BATS)
$16.66 USD
-0.22 (-1.30%)
Updated Jun 6, 2024 10:56 AM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TEVA 16.66 -0.22(-1.30%)
Will TEVA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Other News for TEVA
Teva call volume above normal and directionally bullish
Teva price target raised by $1 at Barclays, here's why
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teva Pharmaceutical (TEVA), Springworks Therapeutics (SWTX) and Gilead Sciences (GILD)
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Teva presents first real-world data from IMPACT-TD Registry study